Design Therapeutics Inc
NASDAQ:DSGN

Watchlist Manager
Design Therapeutics Inc Logo
Design Therapeutics Inc
NASDAQ:DSGN
Watchlist
Price: 7.09 USD -5.47%
Market Cap: 401.4m USD
Have any thoughts about
Design Therapeutics Inc?
Write Note

Intrinsic Value

DSGN's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one DSGN stock under the Base Case scenario is 4.98 USD. Compared to the current market price of 7.09 USD, Design Therapeutics Inc is Overvalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DSGN Intrinsic Value
4.98 USD
Overvaluation 30%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Design Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DSGN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DSGN?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Design Therapeutics Inc

Provide an overview of the primary business activities
of Design Therapeutics Inc.

What unique competitive advantages
does Design Therapeutics Inc hold over its rivals?

What risks and challenges
does Design Therapeutics Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Design Therapeutics Inc.

Provide P/S
for Design Therapeutics Inc.

Provide P/E
for Design Therapeutics Inc.

Provide P/OCF
for Design Therapeutics Inc.

Provide P/FCFE
for Design Therapeutics Inc.

Provide P/B
for Design Therapeutics Inc.

Provide EV/S
for Design Therapeutics Inc.

Provide EV/GP
for Design Therapeutics Inc.

Provide EV/EBITDA
for Design Therapeutics Inc.

Provide EV/EBIT
for Design Therapeutics Inc.

Provide EV/OCF
for Design Therapeutics Inc.

Provide EV/FCFF
for Design Therapeutics Inc.

Provide EV/IC
for Design Therapeutics Inc.

Show me price targets
for Design Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Design Therapeutics Inc?

How accurate were the past Revenue estimates
for Design Therapeutics Inc?

What are the Net Income projections
for Design Therapeutics Inc?

How accurate were the past Net Income estimates
for Design Therapeutics Inc?

What are the EPS projections
for Design Therapeutics Inc?

How accurate were the past EPS estimates
for Design Therapeutics Inc?

What are the EBIT projections
for Design Therapeutics Inc?

How accurate were the past EBIT estimates
for Design Therapeutics Inc?

Compare the revenue forecasts
for Design Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Design Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Design Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Design Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Design Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Design Therapeutics Inc with its peers.

Analyze the financial leverage
of Design Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Design Therapeutics Inc.

Provide ROE
for Design Therapeutics Inc.

Provide ROA
for Design Therapeutics Inc.

Provide ROIC
for Design Therapeutics Inc.

Provide ROCE
for Design Therapeutics Inc.

Provide Gross Margin
for Design Therapeutics Inc.

Provide Operating Margin
for Design Therapeutics Inc.

Provide Net Margin
for Design Therapeutics Inc.

Provide FCF Margin
for Design Therapeutics Inc.

Show all solvency ratios
for Design Therapeutics Inc.

Provide D/E Ratio
for Design Therapeutics Inc.

Provide D/A Ratio
for Design Therapeutics Inc.

Provide Interest Coverage Ratio
for Design Therapeutics Inc.

Provide Altman Z-Score Ratio
for Design Therapeutics Inc.

Provide Quick Ratio
for Design Therapeutics Inc.

Provide Current Ratio
for Design Therapeutics Inc.

Provide Cash Ratio
for Design Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Design Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Design Therapeutics Inc?

What is the current Free Cash Flow
of Design Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Design Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Design Therapeutics Inc

Current Assets 257.2m
Cash & Short-Term Investments 254.1m
Receivables 1.2m
Other Current Assets 2m
Non-Current Assets 4.4m
PP&E 4m
Other Non-Current Assets 427k
Current Liabilities 7.4m
Accounts Payable 1.5m
Accrued Liabilities 6m
Non-Current Liabilities 1.7m
Other Non-Current Liabilities 1.7m
Efficiency

Earnings Waterfall
Design Therapeutics Inc

Revenue
0 USD
Operating Expenses
-60.8m USD
Operating Income
-60.8m USD
Other Expenses
13m USD
Net Income
-47.8m USD

Free Cash Flow Analysis
Design Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

DSGN Profitability Score
Profitability Due Diligence

Design Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

25/100
Profitability
Score

Design Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

DSGN Solvency Score
Solvency Due Diligence

Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DSGN Price Targets Summary
Design Therapeutics Inc

Wall Street analysts forecast DSGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DSGN is 7.14 USD with a low forecast of 4.04 USD and a high forecast of 12.6 USD.

Lowest
Price Target
4.04 USD
43% Downside
Average
Price Target
7.14 USD
1% Upside
Highest
Price Target
12.6 USD
78% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DSGN?

Click here to dive deeper.

Dividends

Design Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for DSGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Design Therapeutics Inc Logo
Design Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

424.7m USD

Dividend Yield

0%

Description

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.

Contact

CALIFORNIA
Carlsbad
6005 Hidden Valley Road, Suite 110
+18582934900.0
www.designtx.com

IPO

2021-03-26

Employees

37

Officers

Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Mr. Pratik Shah Ph.D.
Chief Operating Officer
Dr. Sean Jeffries Ph.D.
Co-Founder & Scientific Advisor
Dr. Aseem Z. Ansari Ph.D.
Chief Accounting Officer
Ms. Julie D. Burgess CPA
General Counsel
Mr. Mustapha Parekh
Consulting Chief Medical Officer
Dr. Jae B. Kim FACC, M.D.
Show More
Controller
Ms. Dawn Giangiulio
Show Less

See Also

Discover More
What is the Intrinsic Value of one DSGN stock?

The intrinsic value of one DSGN stock under the Base Case scenario is 4.98 USD.

Is DSGN stock undervalued or overvalued?

Compared to the current market price of 7.09 USD, Design Therapeutics Inc is Overvalued by 30%.

Back to Top